Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice

Recent advances in type 2 diabetes (T2D) research have highlighted the benefits of sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors, including cardiovascular and renal protection. However, uptake rates of these drugs remain low in patients with T2D, particularly in subpopulations most likely to b...

Descripción completa

Detalles Bibliográficos
Autores principales: Khunti, Kamlesh, Jabbour, Serge, Cos, Xavier, Mudaliar, Sunder, Mende, Christian, Bonaca, Marc, Fioretto, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313799/
https://www.ncbi.nlm.nih.gov/pubmed/35238129
http://dx.doi.org/10.1111/dom.14684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313799/
https://www.ncbi.nlm.nih.gov/pubmed/35238129
http://dx.doi.org/10.1111/dom.14684

Ejemplares similares